Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that the appointment of Mr. Jonathan Gilbert as Executive Chairman of the Board of Directors.
Jonathan Gilbert has over 20 years of leadership, capital raising and public markets expertise. He is considered one of the leaders in both the cannabis and emerging psychedelic sectors, having successfully co-founded and run several companies, leading them to successful M&A transactions.
Jonathan originally joined the Company's Board of Directors in July, 2020 in conjunction with the acquisition of Eleusian Biosciences Corp. which he was co-founder, CEO and director. He is an accomplished leader and business executive with several successful exits in the psychedelics and cannabis sector. Previously, he was the co-founder, CEO and director of SOL Global Investments Corp. (formerly Scythian Biosciences Corp.), a publicly traded research and development company focusing on the prevention and treatment of concussions and traumatic brain injury using a proprietary cannabinoid combination. He was also founder, CEO and a director of Tassili Life Sciences Corp., which was acquired by CSE-listed Champignon Brands Inc. in March 2020. Mr. Gilbert was also executive chairman of Exactus Inc., an OTC listed company focused on farming and production of hemp to be manufactured into cannabidiol (CBD) related products. Jonathan received his BBA in Finance and Financial Management Services from The George Washington University and received his MBA from Kennedy Western University.
"We are extremely pleased to have Jon as our Executive Chairman as his appointment represents an important step in the Company's development and future growth. We are excited to have him take a more active role with the Company and draw upon his expert engagement to advance our innovative research, novel devices and overall expansion efforts," states Thomas Baird, CEO of Lobe. "He has built several psychedelic medicine development companies from the ground floor with successful exit through M&A transactions. We will definitely leverage Jon's vast experience and unparalleled capital markets acumen."
About Lobe Sciences Ltd.
Lobe is a growth-oriented research, technology & services company that provides financial, management, IP and branding support to businesses. The Company operates a portfolio of companies focused on developing transformational medicines and applies refined strategies to help partner companies reach their full potential. Based in Vancouver, BC, Lobe Sciences creates value through acquisitions and development of assets, products and technologies by leveraging its scientific, engineering, branding and operational expertise supported by strong capital markets acumen.
For further information please contact:
Lobe Sciences Ltd.
Thomas Baird, CEO
Tel: (949) 505-5623
THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
Disclaimer for Forward Looking Statements
This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, growth of the business, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; and that the current Board and management may not be able to attain the Company's corporate goals and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.
Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged Goods Products
Released On: 5/19/2021
Lobe Sciences to Present at the Benzinga Global Small Cap Conference
Released On: 5/6/2021
Lobe Sciences Acquires Vitamind Line of Wellness Products
Released On: 5/4/2021
Lobe Sciences Announces Filing of PCT Application
Released On: 4/29/2021
Lobe Sciences Retains Jolt Communications to Increase Investor Awareness
Released On: 2/12/2021
Meet Lobe Sciences A Life Sciences Company Focused on Psychedelic Medicines
Released On: 2/8/2021
Lobe Sciences Announces Pending Patents and Preclinical Research Studies
Released On: 2/5/2021
Lobe Sciences Announces Management Changes and New Director
Released On: 1/18/2021
Lobe Sciences Announces Changes to Board of Directors
Released On: 1/8/2021
Lobe Sciences Announces Jonathan Gilbert Appointed Executive Chairman of the Board of Directors
Released On: 12/14/2020
Lobe Sciences Announces CAD$23,000,000 Sale of Cowlitz Cannabis Option to Ionic Brands Corp.
Released On: 12/1/2020
Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine
Released On: 11/30/2020